Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial
1 other identifier
interventional
40
1 country
1
Brief Summary
Bacterial Vaginosis (BV) is a infectious process of the female genitourinary tract, an important health issue due to the high incidence and high rate of recurrence of the infection. Therefore, new therapeutic modalities are sought with the capacity to minimize drug side effects and reduce cases of recurrence of the disease. The objective of this study is to evaluate the clinical and microbiological response of the 401+/- 5nm blue light emitting diode (LED) in the treatment of women with bacterial vaginosis. The group of women with diagnosis of bacterial vaginosis will be submitted to the light therapy. These women will also be submitted to an evaluation and examination by a ginecologist before and after the therapy. There will also be an evaluation of the clinical condition and about the effects of the light through the questionnaire answered before and after participant's treatment. It's expected that the 41 +/- 5nm LED will destroy the VB demonstrated by laboratory examination and also improves the signs and results analyzed by the gynecologist and participants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 9, 2018
CompletedFirst Posted
Study publicly available on registry
April 17, 2018
CompletedStudy Start
First participant enrolled
October 2, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 20, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 20, 2025
CompletedMarch 5, 2024
March 1, 2024
6.2 years
April 9, 2018
March 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Description of types of cells done by oncology and microflora cytology in women treated by blue LED of 401 +/- 5nm
This exam will be done by the collect of vaginal secretion to analyze types of cells and organisms
15 days
Amount of clue cells quantified by fresh cytology in vaginal secretion of women treated by blu LED of 401 +/- 5nm
This exam will be done by the collect of vaginal secretion using KOH 10%
10 minutes
Value of vaginal pH measurement in women treated by blue LED
This exam will be done by the collect of vaginal secretion using a pH measuring tape to analyse the hydrogen potential in -log 10 \[pH+\] in women treated by blue LED. It will be used the numeric scale of pH value
2 minutes
Identification of bacterial vaginosis by the culture in vaginal secretion of women treated by blue LED
This exam will be done by the collect of vaginal secretion using a Gram exam / culture for bacteria in women treated by blue LED
15 days
Study Arms (1)
Blue LED 401 +/- 5 nm
EXPERIMENTALThe Blue LED 401 +/- 5 nm will be applied in the participant, in a closed room by a physiotherapist for 1 hour. The apparatus will be supported on a tripod, statically, externally, 5 cm away from the vulva abd vaginal region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol consists of only one session. This part of the study will see if there is bactericidal effect of the blue LED.
Interventions
The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
Eligibility Criteria
You may qualify if:
- women with 18 to 65 years old and with diagnosis of bacterial vaginosis
You may not qualify if:
- women with injury seen by Pap smear, or in use of pacemaker, with diagnosis or suspicion of neoplasias, with heart diseases, pregnant or with diagnosis of epilepsy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Centro de Atenção ao Assoalho Pélvicolead
- University of Messinacollaborator
- Salvatore Giovanni Vitale M.D.collaborator
Study Sites (1)
Cebtro de Atebçao ao Assolaho Pévico- Escola Bahiana de Medicina e Saúde Pública
Salvador, Estado de Bahia, 40290000, Brazil
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Patricia Lordelo
Centro de Atenção ao Assoalho Pélvico
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 9, 2018
First Posted
April 17, 2018
Study Start
October 2, 2018
Primary Completion
December 20, 2024
Study Completion
December 20, 2025
Last Updated
March 5, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share